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BACKGROUND 
The human platelet antigen systems consist of antigenic 
polymorphisms that arise from single base pair substitutions leading 
to amino acid changes in platelet glycoproteins.  These 
polymorphisms cause a variety of clinically significant conditions 
where platelet typing is essential for accurate diagnosis and 
subsequent treatment. The aim of this study was to determine the 
allele frequencies of Human Platelet Antigen-1 (HPA-1) and Human 
Platelet Antigen-5 (HPA-5) in the Maltese population and to compare 
these frequencies to those in other populations.  
METHODS 
This study was conducted on a total of 508 population DNA samples. 
Polymerase chain reaction was used to amplify segments of DNA 
spanning the single nucleotide polymorphism of interest for both the 
HPA-1 and HPA-5 systems. A restriction enzyme digest was then used 
to differentiate between the genotypes. The data was analysed by 
gender and nationality.  
RESULTS AND CONCLUSION 
From this study it was determined that, for these two 
polymorphisms, the Maltese population is in Hardy-Weinberg 
equilibrium and that the local allele frequencies are similar to 
frequencies of geographically close populations. The frequencies of 
these two HPA systems are: HPA-1a/1a; 71.6%, HPA-1a/1b; 25.5%, 
HPA-1b/1b; 2.9%, HPA-5a/5a; 77.4%, HPA-5a/5b; 22.0% and HPA-
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Platelet glycoprotein genes are polymorphic 
and these give rise to the platelet surface 
antigens which make up the Human Platelet 
Antigen (HPA) system.  Twenty-nine HPA 
systems on 6 different glycoprotein complexes 
have been identified until now.1 The HPA 
system is an immunogenic system of 
alloantigens which, in the case of 
alloimmunization, may lead to a number of 
clinically significant conditions. Most HPA 
systems are biallelic including a high frequency 
antigen termed as ‘a’ and a lower frequency 
antigen termed as ‘b’.2 The HPA-5 
polymorphism is situated in the GPIa part of 
the glycoprotein GPIaIIa,3 a collagen receptor 
on the surface of platelet membranes. It is 
caused by a single nucleotide polymorphism 
(SNP) on the gene that codes for the GPIa; the 
ITGA2 gene.4 The polymorphism causes a 
single base change of Guanine into Adenine, 
which leads to an amino acid change of 
Glutamic acid to Lysine located between the 
first and second divalent cation binding 
domain of the GPIa.5 On the other hand, the 
HPA-1 polymorphism is located on platelet 
GPIIa at amino acid residue 33.6   The Leucine 
(HPA-1a) to Proline (HPA-1b) SNP is positioned 
in exon 3 of the ITGB3 gene.7 
Alloimmunization against such antigens can 
lead to 3 main clinical conditions which include 
Foetal and Neonatal Alloimmune 
Thrombocytopenia (FNAIT), Post Transfusion 
Purpura (PTP) and Refractoriness to Platelet 
Transfusion (RTP). Other conditions such as 
drug-induced and transplant-associated 
thrombocytopenia have also been reportedly 
associated.1   Recent studies have shown the 
association between some HPA systems and 
Hepatitis C virus (HCV) infection. HCV not only 
invades hepatocytes but also numerous other 
types of cells including B-cells and T-cells,8 
macrophages and monocytes9 and platelets.10 
Studies have also shown the relevance and 
possible association of HPA-5b and HCV 
carriers, where a higher allele frequency of 
HPA-5b was present in HCV carriers.11 
FNAIT is a rare condition, with an incidence 
rate of 1 in 1000 to 1 in 2000 live births. 12-15 
The condition is characterised by either severe 
thrombocytopenia in a newborn at birth or 7 
days after birth, with a platelet count falling 
below 100,000 X 109/L, or foetal intracranial 
haemorrhage (ICH) with no other cause.16 
FNAIT occurs during pregnancy when the 
maternal immune system detects foetal 
platelet specific antigens that are different 
from those present in the mother and in turn 
produces immunoglobulin G antibodies 
against these platelet antigens. These 
antibodies target and destroy foetal 
platelets,17 resulting in extravascular lysis of 
platelets18 and reduced production19. The 
most common HPA to cause FNAIT is 
alloimmunisation against HPA-1a12 causing 75 
% of FNAIT cases followed by 
alloimmunisation to HPA-5b20 causing 16 % of 
all FNAIT cases.   
PTP is an immuno-haematological disorder 
that may be observed in patients a week or 
several weeks after being transfused with a 
blood product containing platelets or platelet 
membranes.21 It has been reported in 1:50,000-
100,000 transfusions22 and results in 
widespread purpura associated with fever, 
chills and bronchospasms around 7 - 10 days 
after receiving the transfusion. In general, such 
patients would have already been exposed to 
allogeneic platelets either through pregnancy 
or previous blood transfusions. The 
alloimmunisation causes the destruction of 
both the foreign alloantigenic platelets as well 
as the patient's own platelets resulting in a 
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severe thrombocytopenia. RTP is a similar but 
milder condition where a low platelet count is 
noted after the patient has received an 
allogeneic random donor platelet 
transfusion.21 
The population frequency of the HPA 
polymorphisms in the Maltese population are 
unknown and determining their frequencies 
would be useful for better detection, 
prevention and prompt treatment of all 
conditions described above, including 
identifying those who may be at risk to 
developing PTP and RTP.  
MATERIALS  AND METHODS 
A total of 508 sequential cord blood samples 
were obtained from an anonymised Cord 
Blood Bank collection maintained by the 
Laboratory of Molecular Genetics (ethical 
approval 48/2002) and consisted of all samples 
from those born over a 2-month period in 
2010. The only demographic data available 
included gender and whether the parents were 
Maltese or foreign.  DNA was extracted from 
these samples using the Salting out 
technique.23 The quantity of the DNA was 
measured using the Nanodrop 2000c 
spectrophotometer and the DNA integrity was 
checked by agarose gel electrophoresis using a 
0.7 % agarose gel.  Each DNA sample was 
diluted to a concentration of 50 ng/µL. 
In order to amplify the HPA-1 and the HPA-5 
gene fragments of 193 bp and 256 bp 
respectively (Figure 1), specific primers were 
selected and polymerase chain reaction (PCR) 
was optimised (Table 1).  The restriction 
enzyme NciI (NEB, UK) was used to digest HPA-
1 PCR products (Figure 2A) using specific 
primers24. For HPA-5, the reverse primer had 
an altered nucleotide (A to T) 3 nucleotides 
from the 3’ end, in order to create a restriction 
enzyme cutting site for restriction enzyme 
DdeI25. The restriction enzyme DdeI (NEB, UK) 
cuts only HPA-5a PCR products but not HPA-5b 
PCR products (Figure 2B). The restriction 
enzyme digest products were separated by 
agarose gel electrophoresis and genotypes 
called based on the fragment pattern.   
Statistical analysis included the calculation of 
allele and genotype frequencies for the 
Maltese population, as well as the χ2 test to 
determine if these were in Hardy-Weinberg 
equilibrium (HWE). Allele and genotype 
frequencies were calculated for the entire 
cord DNA collection as well as the subgroup 
with 2 Maltese parents. The ‘difference 
between 2 population proportions’ calculation 
was used to determine if there were any 
differences between frequencies of the 
subgroup with 2 Maltese parents 
(representing the traditional Maltese gene 
pool) and the collection as a whole 








Figure 1 PCR products of HPA-1 and HPA-5. (A) HPA-1: Lane 1 represents the 100 bp DNA ladder. 
 Lane 2 - 8 are 193 bp PCR products of HPA-1 and Lane 9 is the negative control. (B) HPA-
 5: Lane 1 represents the 100 bp DNA ladder. Lanes 2 - 5 are 256 bp PCR products of HPA-








Table 1 Primer sequences and PCR annealing temperature for HPA-1 and HPA-5. The 
 nucleotide highlighted in bold and underlined is the mismatched nucleotide used to 
 create a DdeI restriction enzyme site.  








5’ TCTTTGGGCTCCTGACTTAC 3’ 





5’ CTCTCATGGAAAATGGCAGTA 3’ 
5’ AGGAAGAGTCTACCTGTTTACTATCTAA 3' 
256 50 
F=forward primer; R=reverse primer; bp=base pairs 
 
RESULTS 
A total of 508 samples were tested to 
represent the Maltese population and these 
consisted of 51 % males and 49 % females.   
The HPA-1 and HPA-5 gene fragments were 
successfully amplified by PCR for these 
samples (Figure 1) and genotyped using NciI 
and DdeI respectively (Figure 2).  
Genotype frequencies were calculated for 
each polymorphism (Table2) and found to be in 
HWE using the Chi-squared test. The allele 
frequencies were determined as follows: 0.844 
for HPA-1a, 0.156 for HPA-1b, 0.884 for HPA-
5a and 0.116 for HPA-5b. From the genotype 
frequencies, the allele frequencies were 
calculated and compared to frequencies of 
other worldwide populations26-36 (Table 3). 
Statistical analysis using the χ2 test confirmed 
that there is no statistically significant 
difference between allele frequencies in Malta 
and the other countries for which data is 
available. 
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Figure 2 Restriction enzyme digest for HPA-1 and HPA-5. (A) NciI digests the HPA-1 PCR fragment 
 of 193 bp when the C nucleotide is present in the HPA-1b polymorphism.  This results in 
 fragmentation into a 33 bp and 160 bp fragment. The top panel shows a typical gel and 
 the bottom panel shows a restriction map. In the gel, Lane 1 shows the 100 bp DNA 
 ladder, Lanes 2, 3, 5-9, 11-14, 16 show HPA-1a homozygous samples with an intact 193 
 bp PCR fragment, Lane 4 is a HPA-1b homozygous sample with a 160 bp fragment and a 
 faint 33 bp fragment, and Lanes 10, 15 and 17 show HPA-1a/1b heterozygous samples. 
 (B) DdeI digests the HPA-5a homozygous PCR fragment of 256bp into 2 fragments of 
 25bp and 231bp. The top panel shows a typical gel and the bottom panel shows a 
 restriction map. In the gel, Lane 1 is the 100 bp DNA ladder, Lanes 2-4, 6, 8, 9 and 11 show 
 HPA-5a homozygous samples which were cleaved into a 231 bp and a non-visible 25 bp 
 fragment, Lane 7 is a HPA-5a/5b heterozygous sample and Lane 10 is a HPA-5b 












Table 2 Genotype frequencies of HPA-1 and HPA-5 in the Maltese. For χ2 tests p-values > 0.05, 









χ2  test P value 
HPA-1 71.6 25.5 2.9 0.486 




Table 3 Allele frequencies for different worldwide populations 
 
Population 
Number of samples 
tested 
Allele frequencies 
HPA-1 HPA-5 HPA-1a HPA-1b HPA-5a HPA-5b 
Greek 21 58 58 0.67 0.33 0.85 0.15 
Tunisian 22 90 90 0.75 0.25 0.78 0.22 
Moroccan Berber 23 110 110 0.75 0.25 0.86 0.14 
Slovenian 24 152 152 0.81 0.19 0.89 0.11 
Swiss 25 500 500 0.81 0.19 0.93 0.07 
Spanish 21, 26 727 454 0.81 0.19 0.88 0.12 
Danish 21, 27 557 427 0.83 0.17 0.92 0.08 
German 21, 28 1583 1643 0.84 0.16 0.92 0.08 
Maltese 489 492 0.84 0.16 0.88 0.12 
French 21 800 6192 0.85 0.15 0.87 0.13 
Italian 21 144 144 0.85 0.15 0.90 0.10 
Irish 21 250 250 0.88 0.12 0.91 0.09 
African 29 6382 922 0.89 0.11 0.84 0.16 
Congolese 30 125 125 0.90 0.10 0.73 0.27 






Genotyping the frequencies of HPA systems is 
useful in collecting data on the genetics of the 
population, but may also be useful in clinical 
scenarios. The allele frequencies of HPA-1 and 
HPA-5 systems tested in 508 cord blood 
samples representing the Maltese population 
were found to be very similar to other 
Caucasian populations which are 
geographically close to Malta, such as the 
Italian, French and German populations (Table 
3). When observing the allele frequencies 
calculated for individuals with one or both 
parents being foreign, the allele frequencies 
were also very similar to southern European 
and northern African populations since most 
immigrants in Malta originate from these 
countries.  
The incidence rate of FNAIT in several 
Caucasian populations was found to be 1 in 
1000 to 1 in 2000 live births. Last reported data 
from the National Statistical Office of Malta 
reported a total of 4444 live births in 2018.37 
Since the HPA-1 and HPA-5 allele frequencies 
in the Maltese population are similar to other 
European countries, one should expect to 
observe approximately 2-3 cases of FNAIT per 
year. The number of cases of FNAIT in Malta 
are much lower [Dr. Laspina personal 
communication]. This low local incidence rate 
of neonates with FNAIT may be due to several 
reasons including neonates with FNAIT being 
born healthy and asymptomatic, or because 
the HPA incompatibility leads to severe 
complications such as miscarriages.  A similarly 
low frequency of FNAIT was observed in the 
Irish population, suggested to be due to under-
recognition of the condition.38 
With the data collected from this study, 
prospective implementations may be 
recommended such as donor and patient 
platelet antigen typing prior to transfusion. 
Anti-HPA screening is not recommended as 
this only indicates a possible risk factor for the 
development of FNAIT and therefore has 
several ethical issues, including the prediction 
and management of alloimmunised 
pregnancies.  Post-natal management of 
FNAIT is therefore more favourable, including 
setting up genotype screening of newborns 
showing clinical symptoms requiring 
transfusion, for appropriate diagnosis and 
treatment with platelet products.  Other 
possible applications of these findings include 
using the optimised methods for genotype 
screening of adults for PTP and RTP, as well as 
genotyping donor and patient prior to platelet 
transfusions.38 
SUMMARY 
• Platelets have different surface antigens 
which make up the Human Platelet 
Antigen (HPA) system.  
• These different glycoproteins on platelet 
surfaces contribute to different clinical 
conditions which include FNAIT, PTP and 
RTP.  
• Each country has different allele 
frequencies for these HPA systems.  
• This study was carried out to determine 
the allele frequency of two of the most 
common HPA systems, HPA-1 & HPA-5, in 
the Maltese population.  
• PCR and a restriction enzyme digest were 
used to genotype 508 random DNA 
samples. 
• The local frequencies of these two HPA 
systems are: HPA-1a/1a; 71.6%, HPA-
1a/1b; 25.5%, HPA-1b/1b; 2.9%, HPA-
5a/5a; 77.4%, HPA-5a/5b; 22.0% and HPA-
5b/5b; 0.6%.  
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